On November 10, 2025, Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (Lilly) where the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.

Under the agreement, Insilico will utilize its validated Pharma.AI platform and deep drug discovery expertise to generate, design, and optimize candidate compounds against targets. Insilico is eligible to receive over $100 million including an upfront, milestone payments, and tiered royalties on net sales upon commercialization of any resulting drug products.

The Wilson Sonsini team that advised Insilico on the transaction includes Alex Key and Kexi Wang.

For more information, please see Insilico's news release. Additional coverage can be found on Fierce Biotech.